Alnylam Hemophilia Drug Gets European Orphan Drug Status | GenomeWeb

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that its Phase I hemophilia drug ALN-AT3 has received orphan drug status from European regulators.

ALN-AT3 comprises siRNAs targeting antithrombin, an endogenous inhibitor of thrombin generation. It is delivered subcutaneously using Alnylam's GalNAc conjugation technology.

Earlier this year, Alnylam released data from the first part of a Phase I trial that showed that single 0.03 mg/kg doses of the drug were able to silence its target by up to 28 to 32 percent in healthy volunteers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.